JaneRSchwebkeMD

Professor, Medicine, University of Alabama School of Medicine

Dr. Schwebke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of WashingtonFellowship, Infectious Disease, 1988 - 1989
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
Northwestern University The Feinberg School of MedicineClass of 1984

Treatment of Bacterial Vaginosis Start of enrollment: 2002 Jul 01
Completed
Phase 4
Control of Trichomoniasis Start of enrollment: 2003 May 01
Completed
Not Applicable
Treatment of Bacterial Vaginosis (BV) With Tinidazole Start of enrollment: 2004 Nov 01
Completed
Phase 4
Bacterial Vaginosis Home Screening to Prevent STDs Start of enrollment: 2008 Jul 28
Completed
Phase 3
Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis Start of enrollment: 2011 Dec 01
Completed
Phase 2
Randomized Controlled Trial of Treatment of Male Partners of Women With BV Start of enrollment: 2015 Feb 01
Completed
Phase 3
"Solana™ Trichomonas Assay Field Study" Start of enrollment: 2015 Oct 15
Completed
Join now to see all

PubMed

11 citations
HPV Vaccine Implementation in STD Clinics—STD Surveillance Network
Elissa Meites, Eloisa Llata, Susan Hariri, Jonathan M. Zenilman, Lisa Longfellow
Sexually Transmitted Diseases. 2012-01-01
39 citations
Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)
Jane R. Schwebke, Ryan Sobel, Janet K Gersten, Steven A Sussman, Samuel N. Lederman
Clinical Infectious Diseases. 2021-09-01
212 citations
Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis
Jacques Ravel, Rebecca M. Brotman, Pawel Gajer, Bing Ma, Melissa Nandy
Microbiome. 2013-12-02

Journal Articles

Safety and Efficacy of a Novel Vaginal Anti-Infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-Blind, Phase...
Jeanne M Marrazzo, Julia C Dombrowski, Angela Pontius, Dwyn Dithmer, Jane Schwebke, Clinical Infectious Diseases

Engineered Phage Endolysin Is a Potential Solution for Recurrent Bacterial VaginosisOctober 28th, 2020
SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal CandidiasisAugust 13th, 2020
Newly Published Research Shows That Hologic’s Molecular Assays for Diagnosing Vaginitis Are More Effective Than Traditional MethodsNovember 25th, 2019
Join now to see all

The UAB Infectious Diseases Training GrantNational Institute Of Allergy And Infectious Diseases2008–2011
UAB Infectious Diseases Training GrantNational Institute Of Allergy And Infectious Diseases2005–2007
Tinidazole For The Treatment Of Bacterial VaginosisNational Institute Of Allergy And Infectious Diseases2004–2007
Therapy And Prevention For Bacterial VaginosisNational Institute Of Allergy And Infectious Diseases2002–2006
Control Of Trichomoniasis -A Paradigm For STD ControlNational Institute Of Allergy And Infectious Diseases2002–2006
Concordance Rates Of Mobiluncus Among Sexual PartnersEunice Kennedy Shriver National Institute Of Child Health &Human Development2003–2004
Bacterial Vaginosis--Pathogenesis And Impact On Sexually Transmitted DiseasesNational Institute Of Allergy And Infectious Diseases1995–2002
Lower Genital Tract Infection In A Rural PopulationEunice Kennedy Shriver National Institute Of Child Health &Human Development1996–2000